BLOGIR-3, tablets 5 mg 10 pcs

How to take, the dosage

Orally, regardless of meals. It is necessary to open the blister carefully and take out the tablet without breaking it. The tablet for dissolution is placed on the tongue, where it dissolves, and then it is swallowed with saliva, without drinking water or other liquids. The tablet should be taken immediately after opening the blister.

Adults and teenagers over 12 years old: 1 tablet (5 mg) 1 time per day to reduce symptoms of allergic rhinitis (including seasonal and year-round allergic rhinitis) and urticaria.

In seasonal (intermittent) allergic rhinitis (with symptoms lasting less than 4 days per week or less than 4 weeks per year) the course of the disease should be evaluated. If the symptoms disappear, the drug should be discontinued, and if the symptoms reappear, the drug should be resumed.

In case of year-round (persistent) allergic rhinitis (with symptoms lasting more than 4 days a week or more than 4 weeks a year) the drug should be taken during the whole period of allergen exposure.

Interaction

No clinically significant changes in plasma concentrations of desloratadine were found during multiple co-administration of desloratadine with ketoconazole, erythromycin, azithromycin, fluoxetine and cimetidine. BLOGIR-3® does not increase the effect of alcohol on the central nervous system.

Food intake has no effect on the effectiveness of the drug.

Special Instructions

Impact on the ability to drive and operate vehicles

In the recommended dose, the drug does not affect the ability to drive or operate machinery.

Now, however, in very rare cases, some patients may experience somnolence while taking desloratadine, which may affect their ability to drive or operate machinery.

Contraindications

Hypersensitivity to the drug components; pregnancy and lactation; age under 12 years; phenylketonuria.

Side effects

The frequency of adverse reactions is classified according to the recommendations of the World Health Organization: very common – at least 10%; common – at least 1%, but less than 10%; infrequent – at least 0.1%, but less than 1%; rare – at least 0.01%, but less than 0.1%; very rare – less than 0.01%, including individual reports.

Overdose

During clinical trials no clinically significant adverse effects were observed when using desloratadine in doses up to 45 mg (9 times the therapeutic dose).

Treatment: In case of overdose, standard measures aimed at removing the active substance from the gastrointestinal tract are taken. Symptomatic and supportive therapy is recommended.

Desloratadine is not excreted by hemodialysis, the effectiveness of peritoneal dialysis has not been established.